|
Impact of EGFR amplification status in newly diagnosed glioblastoma treated with Stupp protocol. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Monteris Medical |
Leadership - Monteris Medical |
Stock and Other Ownership Interests - Monteris Medical |
Honoraria - Monteris Medical |
Consulting or Advisory Role - Monteris Medical |
Speakers' Bureau - Monteris Medical |
Research Funding - Monteris Medical |
Patents, Royalties, Other Intellectual Property - Monteris Medical |
Expert Testimony - Monteris Medical |
Travel, Accommodations, Expenses - Monteris Medical |
Other Relationship - Monteris Medical |
|
|
No Relationships to Disclose |
|
Alireza Mohammad Mohammadi |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie |
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Mylan (Inst); Neonc Technologies (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Stemline Therapeutics (Inst) |
Travel, Accommodations, Expenses - Stemline Therapeutics |
|
|
No Relationships to Disclose |
|
|
Honoraria - Chrysalis biotherapeutics |
Consulting or Advisory Role - Chrysalis biotherapeutics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - doctible; MimiVax |
Honoraria - Elsevier; Prime Education; Prime Oncology |
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; CBT Pharmaceuticals; Flatiron Health; Kadmon; Karyopharm Therapeutics; Monteris Medical; Varian Medical Systems; VBI Vaccines |
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst) |